First Reported Successful Femoral Valve-in-Valve Transcatheter Aortic Valve Replacement Using the Edwards Sapien 3 Valve.

Détails

ID Serval
serval:BIB_DF70082F2BAB
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Etude de cas (case report): rapporte une observation et la commente brièvement.
Collection
Publications
Titre
First Reported Successful Femoral Valve-in-Valve Transcatheter Aortic Valve Replacement Using the Edwards Sapien 3 Valve.
Périodique
Journal of Invasive Cardiology
Auteur(s)
Fournier S., Monney P., Roguelov C., Zuffi A., Iglesias J.F., Qanadli S.D., Courbon C., Eeckhout E., Muller O.
ISSN
1557-2501 (Electronic)
ISSN-L
1042-3931
Statut éditorial
Publié
Date de publication
10/2015
Peer-reviewed
Oui
Volume
27
Numéro
10
Pages
E220-E223
Langue
anglais
Notes
Publication types: Journal Article
Résumé
OBJECTIVES: Management of degenerated aortic valve bioprosthesis classically requires redo surgery, but transcatheter aortic valve-in-valve implantation is becoming a valid alternative in selected cases. In the case of a degenerated Mitroflow bioprosthesis, TAVR is associated with an additional challenge due to a specific risk of coronary occlusion. We aimed to assess the safety and feasibility of transfemoral valve-in-valve implantation of the new Edwards Sapien 3 (Edwards Lifesciences) in a degenerated Mitroflow bioprosthesis (Sorin Group, Inc).
METHODS: We report here the safety and feasibility of transfemoral valve-in-valve implantation of a 23 mm Edwards Sapien 3 in a degenerated 25 mm Mitroflow valve and describe the specific assessment of the risk of coronary obstruction using a multi-imaging modality.
RESULTS: The final result showed an absence of aortic regurgitation and a mean transvalvular gradient of 14 mm Hg. The patient had no major adverse cardiovascular events at 30-day follow-up.
CONCLUSION: Transcatheter valve-in-valve implantation of an Edwards Sapien 3 in a degenerated Mitroflow is feasible and safe, considering a careful assessment of the risk of coronary obstruction with Mitroflow bioprosthesis due to leaflets mounted externally to the stent.
Pubmed
Web of science
Création de la notice
05/10/2015 15:07
Dernière modification de la notice
20/08/2019 17:03
Données d'usage